Know the New Drugs and Clinical Trials (Amendment) Rules - 2026

In 2026, the Ministry of Health and Family Welfare (MoHFW) along with the Central Drugs Standard Control Organization (CDSCO) introduced major regulatory updates under the New Drugs and Clinical Trials (NDCT) Rules and the Drugs Rules, 1945. These amendments significantly streamline pharmaceutical research, simplify approvals, and strengthen manufacturing oversight in India.

The new framework focuses on accelerating drug development, improving patient safety, and aligning India’s regulatory system with global standards. Below is a detailed breakdown of the key changes introduced under the 2026 amendment rules.

New Drugs and Clinical Trials (Amendment) Rules, 2026

The NDCT Amendment Rules, 2026 primarily focus on reducing regulatory delays and improving ease of research for pharmaceutical companies.

Prior Intimation Instead of Test Licenses

A major reform introduced in 2026 is the replacement of the traditional Test License system for non-commercial manufacturing.

Now, for small-scale manufacturing of new drugs used for:

• Research and Development (R&D)
• Bioequivalence studies
• Analytical testing

Companies are no longer required to obtain a formal Test License. Instead, they must follow a Prior Intimation Mechanism through the CDSCO SUGAM Portal.

This significantly reduces procedural delays and simplifies early-stage drug development approvals.

High-Risk Category Exceptions

Despite simplification, prior approval is still mandatory for high-risk substances, including:

• Narcotics and psychotropic substances
• Cytotoxic drugs
• Biologics containing live microorganisms
• Sex hormones
• Beta-lactam antibiotics

These categories require stricter control due to higher safety risks.

Impact of the Amendment

This reform is expected to reduce drug development timelines by up to 90 days, enabling faster innovation and quicker clinical research execution in India.

Drugs (Amendment) Rules, 2026 (G.S.R. 135(E))

These amendments modify the foundational Drugs Rules, 1945, with a strong focus on quality assurance and patient safety.

Pyrogen and Bacterial Endotoxin Testing (Rule 121A Update)

One of the key updates is in Rule 121A, which now mandates:

• All parenteral drug formulations must comply with bacterial endotoxin and pyrogen testing requirements
• Aqueous solvents used in injectables must also meet these standards
• Testing must strictly follow the latest edition of the Indian Pharmacopoeia

This ensures higher safety standards for injectable medicines.

Competent Person Supervision Requirement

Another important amendment strengthens retail and wholesale drug control.

Sales licenses such as:

• Form 20B
• Form 20G
• Form 21B

must now operate under the personal supervision of a designated competent person.

This ensures accountability and reduces the risk of unauthorized or unsafe drug distribution.

Draft Rules on Manufacturing Changes

The government has also introduced draft guidelines to standardize post-approval changes in drug manufacturing.

Classification of Changes

Manufacturing and quality changes are now categorized into three levels:

• Major Changes → Require prior approval from CDSCO
• Moderate Changes → Require prior regulatory approval
• Minor Changes → Only annual reporting is required

This classification system helps streamline regulatory oversight while maintaining product safety and quality.

Advantages of the Updated Rules

1. Stronger Patient Protections

The amendments emphasize safety, requiring CROs to report adverse events and provide compensation for trial-related injuries.

2. Faster Drug Licensing

The simplified process to apply for a drug license in Delhi or elsewhere reduces delays, fostering innovation.

3. Global Alignment

By meeting international standards, these rules enhance India's reputation as a trusted destination for clinical trials.

4. Improved Accountability

Mandatory registration for CROs ensures transparency and regulatory control.

Challenges for Stakeholders

While the NDCT Rules, 2026 bring many benefits, they also introduce certain challenges:

♦ The ₹5,00,000 registration fee may deter smaller organizations
♦ Compliance with extensive documentation can be resource-intensive

To overcome these challenges, businesses must thoroughly prepare before applying for a drug license in Delhi or other locations.

Compliance and Operational Guidelines

Registered CROs must:

♦ Keep trial records for at least five years
♦ Notify the CLA of changes in ownership within one month
♦ Allow inspections by CLA-authorized officials

Non-compliance can lead to penalties, including suspension or cancellation of registration.

Shaping the Future of Clinical Trials

The NDCT Rules, 2026 represent a forward-thinking approach and a bold step toward regulating clinical trials in India.

Businesses must understand these rules to obtain a drug license. Those seeking to apply for a drug license in Delhi must navigate the updated framework carefully to ensure compliance.

Conclusion

The New Drugs and Clinical Trials (Amendment) Rules, 2026 are designed to streamline processes and enhance patient safety while strengthening India’s clinical research ecosystem.

For organizations aiming to secure a drug license, these updates provide a clear and structured roadmap. Whether applying for a drug license in Delhi or elsewhere, adhering to the NDCT Rules, 2026 is essential for compliance and smooth approval.

Get Drug License Registration with Expert Support

Don’t let regulatory complexity, documentation requirements, and compliance procedures delay your clinical research or pharmaceutical operations. Whether you are a pharmaceutical company, CRO, startup, or healthcare organization, obtaining a drug license is essential for legally operating in India.

At PSR Compliance, we simplify the entire drug licensing process—from documentation and application filing to regulatory coordination and approval support.

👉 Get your Drug License Registration completed quickly and compliantly

📞 Call us now: +91 8796104190

📧 Email: support@psrcompliance.com

Frequently Asked Questions (FAQs)

1. What is the New Drugs and Clinical Trials (Amendment) Rules, 2026?

It is a regulatory update by MoHFW and CDSCO that simplifies clinical trial approvals and strengthens drug manufacturing oversight in India.

2. What is the biggest change in the NDCT Rules, 2026?

The replacement of test licenses with a prior intimation system for non-commercial drug manufacturing via the CDSCO SUGAM portal.

3. Is approval still required for all drug categories?

No. High-risk categories like narcotics, cytotoxins, and biologics still require prior approval from CDSCO.

4. What is the SUGAM portal used for?

It is the online CDSCO platform used for submitting prior intimation, approvals, and regulatory applications.

5. How do these rules affect drug licensing in India?

They simplify and speed up the approval process, making it easier to apply for a drug license in Delhi and other regions.

6. What is Rule 121A amendment about?

It mandates bacterial endotoxin and pyrogen testing for injectable drugs as per Indian Pharmacopoeia standards.

7. What happens if CROs do not comply with these rules?

Non-compliance may result in suspension or cancellation of registration and regulatory penalties.